Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) and ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Tactile Systems Technology and ClearPoint Neuro, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tactile Systems Technology | 0 | 2 | 4 | 0 | 2.67 |
| ClearPoint Neuro | 1 | 0 | 2 | 0 | 2.33 |
Tactile Systems Technology currently has a consensus price target of $38.40, suggesting a potential upside of 68.57%. ClearPoint Neuro has a consensus price target of $25.67, suggesting a potential upside of 91.87%. Given ClearPoint Neuro’s higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than Tactile Systems Technology.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Tactile Systems Technology | 7.10% | 11.49% | 9.17% |
| ClearPoint Neuro | -81.76% | -188.09% | -40.88% |
Insider & Institutional Ownership
83.4% of Tactile Systems Technology shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 2.1% of Tactile Systems Technology shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Tactile Systems Technology and ClearPoint Neuro”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tactile Systems Technology | $329.52 million | 1.57 | $19.09 million | $1.08 | 21.09 |
| ClearPoint Neuro | $36.97 million | 11.04 | -$25.54 million | ($1.18) | -11.34 |
Tactile Systems Technology has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Tactile Systems Technology has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Summary
Tactile Systems Technology beats ClearPoint Neuro on 10 of the 14 factors compared between the two stocks.
About Tactile Systems Technology
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.
